HomepageCAMRF • OTCMKTS
add
Camurus AB
Vorige slotkoers
$Â 71,00
Jaar-range
$Â 50,97 - $Â 71,07
Beurswaarde
39,11Â mld. SEK
Gem. volume
7,00
Koers/winst
-
Dividendrendement
-
Primaire beurs
STO
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (SEK) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 675,50Â mln. | 51,84% |
Bedrijfskosten | 342,31Â mln. | 3,59% |
Netto inkomsten | 244,79Â mln. | 229,91% |
Netto winstmarge | 36,24 | 117,27% |
Winst per aandeel | 4,08 | 226,40% |
EBITDA | 298,33Â mln. | 245,49% |
Effectief belastingtarief | 20,27% | — |
Balans
Totale activa
Totale passiva
| (SEK) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 3,35Â mld. | 30,40% |
Totale activa | 4,42Â mld. | 28,90% |
Totale passiva | 553,52Â mln. | 9,89% |
Totaal aandelenvermogen | 3,87 mld. | — |
Uitstaande aandelen | 59,42 mln. | — |
Koers-boekwaardeverhouding | 1,09 | — |
Rendement op activa | 17,40% | — |
Rendement op kapitaal | 19,29% | — |
Kasstroom
Nettomutatie in liquide middelen
| (SEK) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 244,79Â mln. | 229,91% |
Operationele kasstroom | 375,78Â mln. | 280,55% |
Kasstroom uit beleggingen | -27,41Â mln. | -1.325,33% |
Kasstroom uit financiering | 121,94Â mln. | -37,94% |
Nettomutatie in liquide middelen | 469,37Â mln. | 60,07% |
Vrije kasstroom | 230,39Â mln. | 238,08% |
Over
Camurus AB is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap.
Camurus was founded by scientists in biophysical, food, and pharmaceutical chemistry with expertise in lipid phase structures. The company provides nanoscale drug-delivery systems for development of high-value therapeutics. Wikipedia
Opgericht
1991
Website
Werknemers
267
